Nektar Therapeutics (NKTR) Tops Q1 EPS Views
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/22/2026
- S&P 500, Nasdaq close lower, dragged by Alphabet and megacap tech; focus on Iran
- Oil settles down more 3% after US-Iran talks signal easing supply risks
- Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
- Alan Greenspan, influential former Federal Reserve chair, dies at 100
- Buy gold stocks as valuations are cheap amid macro tension: BofA
- CoreWeave trains DeepSeek-V3 in two minutes in MLPerf benchmark
- Needham Starts NeoVolta (NEOV) at Buy
- Spain's ex-transport minister sentenced to 24 years for corruption
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
Nektar Therapeutics Reports Financial Results for the First Quarter of 2015
April 30, 2015 4:15 PM EDTSAN FRANCISCO, April 30, 2015 /PRNewswire/ --Â Nektar Therapeutics (Nasdaq: NKTR) today reported its financial results for the first quarter ended March 31, 2015.
Cash and investments in marketable securities at March 31, 2015 were $325.8 million as compared to $262.8 million at December 31, 2014. Our cash and investments in marketable securities at March 31, 2015 includes a $100.0 million milestone payment received from AstraZeneca in Q1 2015 for the first commercial sale of Movantik(naloxegol) in the U.S.
"The recent U.S. launch of Movantik by AstraZeneca is progressing well and this first-in-class medicine to treat OIC is now being... More
